Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 6/20 | 1.00 |
| ▸ | EYA3 | Q99504 | 5/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.81 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.60 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.56 |
| ▸ | THRA | P10827 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28245012 | 0.89 | CYP2C19 (0.79) | CYP2C19EYA3CYP2C9SLC22A12LMNA | |
| SCHEMBL28245008 | 0.88 | CYP2C19 (0.79) | CYP2C19EYA3CYP2C9SLC22A12LMNA | |
| SCHEMBL28245013 | 0.86 | CYP2C19 (0.75) | CYP2C19EYA3CYP2C9SLC22A12LMNA | |
| SCHEMBL8994709 | 0.83 | CYP2C19 (1.00) | CYP2C19EYA3CYP2C9HTTKDM7A | |
| SCHEMBL28245011 | 0.83 | CYP2C19 (0.71) | CYP2C19EYA3CYP2C9SLC22A12LMNA | |
| SCHEMBL11846277 | 0.83 | CYP2C19 (0.70) | CYP2C19EYA3CYP2C9SLC22A12LMNA | |
| SCHEMBL14552023 | 0.81 | HTT (0.70) | CYP2C19EYA3CYP2C9SLC22A12LMNA | |
| SCHEMBL31485743 | 0.81 | LMNA (0.74) | CYP2C19EYA3CYP2C9SLC22A12LMNA | |
| SCHEMBL28244402 | 0.81 | HTT (0.70) | CYP2C19EYA3CYP2C9LMNAHTT | |
| SCHEMBL3219908 | 0.80 | EYA3 (1.00) | CYP2C19EYA3CYP2C9LMNATHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130312-A1 | INHIBITORS OF EYA3-PROTEIN TYROSINE PHOSPHATASE IN DNA DAMAGE REPAIR SIGNALING OF PULMONARY ARTERIAL HYPERTENSION | CHILDRENS HOSPITAL MED CT (US) | 2021-05-06 | — | — | US | disclosed |
| CN-108484546-B | A kind of preparation method of 2- methyl -3- benzoyl benzofuran derivatives | 江南大学 | 2019-11-08 | — | — | CN | disclosed |
| WO-2019195118-A1 | INHIBITORS OF EYA3-PROTEIN TYROSINE PHOSPHATASE IN DNA DAMAGE REPAIR SIGNALING OF PULMONARY ARTERIAL HYPERTENSION | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2019-10-10 | — | — | WO | disclosed |
| US-10221151-B2 | Use of small molecule inhibitors targeting EYA tyrosine phosphatase | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2019-03-05 | — | — | US | disclosed |
| CN-108484546-A | A kind of preparation method of 2- methyl -3- benzoyl benzofuran derivatives | 江南大学 | 2018-09-04 | — | — | CN | disclosed |
| US-9962362-B2 | Use of small molecule inhibitors targeting EYA tyrosine phosphatase | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2018-05-08 | — | — | US | disclosed |
| US-9962362-B2 | Use of small molecule inhibitors targeting EYA tyrosine phosphatase | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170349562-A1 | USE OF SMALL MOLECULE INHIBITORS TARGETING EYA TYROSINE PHOSPHATASE | CHILDREN'S HOSPITAL MEDICAL CENTER | 2017-12-07 | — | — | US | disclosed |
| US-20170349562-A1 | USE OF SMALL MOLECULE INHIBITORS TARGETING EYA TYROSINE PHOSPHATASE | CHILDREN'S HOSPITAL MEDICAL CENTER | 2017-12-07 | — | — | US | disclosed |
| US-9725430-B2 | Use of small molecule inhibitors targeting EYA tyrosine phosphatase | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2017-08-08 | — | — | US | disclosed |
| US-5567728-A | BENZOYL BENZOFURAN DERIVATIVES USED TO PREVENT OR TREAT CARDIAC ARRHYTHMIA | KAROBIO AKTIEBOLAG (SE) | 1996-10-22 | — | — | US | disclosed |
| EP-0584186-B1 | RECEPTOR LIGANDS | KAROBIO AB (SE) | 1996-08-21 | — | — | EP | disclosed |
| EP-0584186-A1 | RECEPTOR LIGANDS. | KAROBIO AB (SE) | 1994-03-02 | — | — | EP | disclosed |
| US-5274000-A | 2-alkyl-3-carboxyalkylene or amidoalkyleneoxy-1,4-phenylene | KOTOBUKI SEIYAKU COMPANY LIMITED (JP) | 1993-12-28 | — | — | US | disclosed |
| US-5175184-A | Diuretics | KOTOBUKI SEIYAKU COMPANY LIMITED (JP) | 1992-12-29 | — | — | US | disclosed |
| WO-1992020331-A1 | RECEPTOR LIGANDS | KAROBIO AKTIEBOLAG (SE) | 1992-11-26 | — | — | WO | disclosed |
| US-5004750-A | Diuretics | KOTOBUKI SEIYAKU COMPANY LIMITED (JP) | 1991-04-02 | — | — | US | disclosed |
| US-4797415-A | DIURETICS FOR GOUT | KOTOBUKI SEIYAKU COMPANY LIMITED (JP) | 1989-01-10 | — | — | US | disclosed |
| US-3983245-A | CORONARY VASODILATORS | SMITHKLINE CORPORATION (US) | 1976-09-28 | — | — | US | disclosed |
| US-3975537-A | SUBSTITUTED BENZOFURANS | SMITH KLINE (US) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349562-A1 | USE OF SMALL MOLECULE INHIBITORS TARGETING EYA TYROSINE PHOSPHATASE | EYA2, EYA3, PTPRO | CYP2C19 4712/4885EYA3 2/4885CYP2C9 4758/4885 |
| US-10221151-B2 | Use of small molecule inhibitors targeting EYA tyrosine phosphatase | EYA2, EYA3, PTPRO | CYP2C19 4712/4885EYA3 2/4885CYP2C9 4758/4885 |
| US-20210130312-A1 | INHIBITORS OF EYA3-PROTEIN TYROSINE PHOSPHATASE IN DNA DAMAGE REPAIR SIGNALING OF PULMONARY ARTERIAL HYPERTENSION | EYA3, EYA2, LIG3 | CYP2C19 4022/4885EYA3 1/4885CYP2C9 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.